On October 7, WUXI BIO fell 3.11% at open in regular trading, trading at HKD 56.1/share, with Turnover of HKD 138 million.

The decline was driven primarily by profit-taking pressure following the previous session's intraday gain of 3.16%, as well as broader weakness across the CXO sector. The company recently reported interim results with revenue of RMB 11.787 billion and adjusted net profit of RMB 3.937 billion, with gross margin improving to 46.2%. It also cancelled approximately 39.82 million repurchased shares, reducing the free float. However, sector sentiment weighed on the stock, as INSILICO fell 4.55%, JOINN declined 4.35%, XTALPI lost 2.47%, and GENSCRIPT BIO dropped 10.46%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)